BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
NCT01669798
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Interventions
DRUG:
BIBF 1120
Sponsor
AA Secord
Collaborators
[object Object]